Brian T Steffen1, Weihua Guan1, Alan T Remaley1, Pathmaja Paramsothy1, Susan R Heckbert1, Robyn L McClelland1, Philip Greenland1, Erin D Michos1, Michael Y Tsai2. 1. From the Department of Laboratory Medicine and Pathology (B.T.S., M.Y.T.) and Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Laboratory Medicine, National Institutes of Health Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (A.T.R.); University of Washington School of Medicine, Department of Medicine, Division of Cardiology, University of Washington Medical Center, Seattle (P.P.); Cardiovascular Health Research Unit, Department of Epidemiology, School of Public Health (S.R.H.) and Department of Biostatistics (R.L.M.), University of Washington, Seattle; Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (P.G.); and Johns Hopkins School of Medicine, Department of Medicine, Division of Cardiology, Johns Hopkins University, Baltimore, MD (E.D.M.). 2. From the Department of Laboratory Medicine and Pathology (B.T.S., M.Y.T.) and Division of Biostatistics, School of Public Health (W.G.), University of Minnesota, Minneapolis; Department of Laboratory Medicine, National Institutes of Health Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (A.T.R.); University of Washington School of Medicine, Department of Medicine, Division of Cardiology, University of Washington Medical Center, Seattle (P.P.); Cardiovascular Health Research Unit, Department of Epidemiology, School of Public Health (S.R.H.) and Department of Biostatistics (R.L.M.), University of Washington, Seattle; Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (P.G.); and Johns Hopkins School of Medicine, Department of Medicine, Division of Cardiology, Johns Hopkins University, Baltimore, MD (E.D.M.). tsaix001@umn.edu.
Abstract
OBJECTIVE: The American College of Cardiology and American Heart Association have issued guidelines indicating that the contribution of apolipoprotein B-100 (ApoB) to cardiovascular risk assessment remains uncertain. The present analysis evaluates whether lipoprotein particle measures convey risk of coronary heart disease (CHD) in 4679 Multi-Ethnic Study of Atherosclerosis (MESA) participants. APPROACH AND RESULTS: Cox regression analysis was performed to determine associations between lipids or lipoproteins and primary CHD events. After adjustment for nonlipid variables, lipoprotein particle levels in fourth quartiles were found to convey significantly greater risk of incident CHD when compared to first quartile levels (hazard ratio [HR]; 95% confidence interval [CI]): ApoB (HR, 1.84; 95% CI, 1.25-2.69), ApoB/ApoA-I (HR, 1.91; 95% CI, 1.32-2.76), total low-density lipoprotein-particles (LDL-P; HR, 1.77; 95% CI, 1.21-2.58), and the LDL-P/HDL-P (high-density lipoprotein-P) ratio (HR, 2.28; 95% CI, 1.54-3.37). Associations between lipoprotein particle measures and CHD were attenuated after adjustment for standard lipid panel variables. Using the American Heart Association/American College of Cardiology risk calculator as a baseline model for CHD risk assessment, significant net reclassification improvement scores were found for ApoB/ApoA-I (0.18; P=0.007) and LDL-P/high-density lipoprotein-P (0.15; P<0.001). C-statistics revealed no significant increase in CHD event discrimination for any lipoprotein measure. CONCLUSIONS: Lipoprotein particle measures ApoB/ApoA-I and LDL-P/high-density lipoprotein-P marginally improved net reclassification improvement scores, but null findings for corresponding c-statistic are not supportive of lipoprotein testing. The attenuated associations of lipoprotein particle measures with CHD after the adjustment for lipids indicate that their measurement does not detect risk that is unaccounted for by the standard lipid panel. However, the possibility that lipoprotein measures may identify CHD risk in a subpopulation of individuals with normal cholesterol, but elevated lipoprotein particle numbers cannot be ruled out.
OBJECTIVE: The American College of Cardiology and American Heart Association have issued guidelines indicating that the contribution of apolipoprotein B-100 (ApoB) to cardiovascular risk assessment remains uncertain. The present analysis evaluates whether lipoprotein particle measures convey risk of coronary heart disease (CHD) in 4679 Multi-Ethnic Study of Atherosclerosis (MESA) participants. APPROACH AND RESULTS: Cox regression analysis was performed to determine associations between lipids or lipoproteins and primary CHD events. After adjustment for nonlipid variables, lipoprotein particle levels in fourth quartiles were found to convey significantly greater risk of incident CHD when compared to first quartile levels (hazard ratio [HR]; 95% confidence interval [CI]): ApoB (HR, 1.84; 95% CI, 1.25-2.69), ApoB/ApoA-I (HR, 1.91; 95% CI, 1.32-2.76), total low-density lipoprotein-particles (LDL-P; HR, 1.77; 95% CI, 1.21-2.58), and the LDL-P/HDL-P (high-density lipoprotein-P) ratio (HR, 2.28; 95% CI, 1.54-3.37). Associations between lipoprotein particle measures and CHD were attenuated after adjustment for standard lipid panel variables. Using the American Heart Association/American College of Cardiology risk calculator as a baseline model for CHD risk assessment, significant net reclassification improvement scores were found for ApoB/ApoA-I (0.18; P=0.007) and LDL-P/high-density lipoprotein-P (0.15; P<0.001). C-statistics revealed no significant increase in CHD event discrimination for any lipoprotein measure. CONCLUSIONS: Lipoprotein particle measures ApoB/ApoA-I and LDL-P/high-density lipoprotein-P marginally improved net reclassification improvement scores, but null findings for corresponding c-statistic are not supportive of lipoprotein testing. The attenuated associations of lipoprotein particle measures with CHD after the adjustment for lipids indicate that their measurement does not detect risk that is unaccounted for by the standard lipid panel. However, the possibility that lipoprotein measures may identify CHD risk in a subpopulation of individuals with normal cholesterol, but elevated lipoprotein particle numbers cannot be ruled out.
Authors: John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum Journal: J Am Coll Cardiol Date: 2008-04-15 Impact factor: 24.094
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: B Lamarche; S Moorjani; P J Lupien; B Cantin; P M Bernard; G R Dagenais; J P Després Journal: Circulation Date: 1996-08-01 Impact factor: 29.690
Authors: A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch Journal: Circulation Date: 2001-09-04 Impact factor: 29.690
Authors: James D Otvos; Samia Mora; Irina Shalaurova; Philip Greenland; Rachel H Mackey; David C Goff Journal: J Clin Lipidol Date: 2011 Mar-Apr Impact factor: 4.766
Authors: Michael Y Tsai; Brian T Steffen; Weihua Guan; Robyn L McClelland; Russell Warnick; Joseph McConnell; Daniel M Hoefner; Alan T Remaley Journal: Arterioscler Thromb Vasc Biol Date: 2013-11-14 Impact factor: 8.311
Authors: William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino Journal: J Clin Lipidol Date: 2007-12 Impact factor: 4.766
Authors: Chiadi E Ndumele; Kunihiro Matsushita; Brad Astor; Salim S Virani; Samia Mora; Emma K Williams; Ron C Hoogeveen; Roger S Blumenthal; A Richey Sharrett; Christie M Ballantyne; Josef Coresh Journal: Eur J Prev Cardiol Date: 2012-10-29 Impact factor: 7.804
Authors: Brian T Steffen; Weihua Guan; Alan T Remaley; James H Stein; Mathew C Tattersall; Joel Kaufman; Michael Y Tsai Journal: J Clin Lipidol Date: 2017-07-12 Impact factor: 4.766
Authors: Laura A McGuinn; Alexandra Schneider; Robert W McGarrah; Cavin Ward-Caviness; Lucas M Neas; Qian Di; Joel Schwartz; Elizabeth R Hauser; William E Kraus; Wayne E Cascio; David Diaz-Sanchez; Robert B Devlin Journal: Environ Int Date: 2018-11-13 Impact factor: 9.621
Authors: Paramjit K Sandhu; Salma M A Musaad; Alan T Remaley; Stephanie S Buehler; Sonya Strider; James H Derzon; Hubert W Vesper; Anne Ranne; Colleen S Shaw; Robert H Christenson Journal: J Appl Lab Med Date: 2016-08-01
Authors: Ying Zhang; Alicia J Jenkins; Arpita Basu; Julie A Stoner; Maria F Lopes-Virella; Richard L Klein; Timothy J Lyons Journal: J Lipid Res Date: 2015-12-09 Impact factor: 5.922
Authors: Sara Fernández-Castillejo; Rosa-Maria Valls; Olga Castañer; Laura Rubió; Úrsula Catalán; Anna Pedret; Alba Macià; Maureen L Sampson; María-Isabel Covas; Montserrat Fitó; Maria-José Motilva; Alan T Remaley; Rosa Solà Journal: Mol Nutr Food Res Date: 2016-05-06 Impact factor: 5.914
Authors: Jing Cao; Sarah O Nomura; Brian T Steffen; Weihua Guan; Alan T Remaley; Amy B Karger; Pamela Ouyang; Erin D Michos; Michael Y Tsai Journal: J Clin Lipidol Date: 2019-11-29 Impact factor: 4.766
Authors: Alexander C Razavi; Rhanderson Cardoso; Omar Dzaye; Matthew Budoff; George Thanassoulis; Wendy S Post; Sanjiv Shah; Daniel S Berman; Khurram Nasir; Michael J Blaha; Seamus P Whelton Journal: Am J Cardiol Date: 2021-07-27 Impact factor: 3.133
Authors: Zhe Wang; Ani Manichukal; David C Goff; Samia Mora; Jose M Ordovas; Nicholas M Pajewski; Wendy S Post; Jerome I Rotter; Michele M Sale; Stephanie A Santorico; David Siscovick; Michael Y Tsai; Donna K Arnett; Stephen Rich; Alexis C Frazier-Wood Journal: Hum Genet Date: 2017-03-28 Impact factor: 5.881